Department of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar, Tamil Nadu 608002, India.
Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Mediators Inflamm. 2021 Jul 31;2021:9982954. doi: 10.1155/2021/9982954. eCollection 2021.
Alzheimer's disease (AD) is a neurodegenerative disorder with no clear causative event making the disease difficult to diagnose and treat. The pathological hallmarks of AD include amyloid plaques, neurofibrillary tangles, and widespread neuronal loss. Amyloid-beta has been extensively studied and targeted to develop an effective disease-modifying therapy, but the success rate in clinical practice is minimal. Recently, neuroinflammation has been focused on as the event in AD progression to be targeted for therapies. Various mechanistic pathways including cytokines and chemokines, complement system, oxidative stress, and cyclooxygenase pathways are linked to neuroinflammation in the AD brain. Many cells including microglia, astrocytes, and oligodendrocytes work together to protect the brain from injury. This review is focused to better understand the AD inflammatory and immunoregulatory processes to develop novel anti-inflammatory drugs to slow down the progression of AD.
阿尔茨海默病(AD)是一种神经退行性疾病,没有明确的致病事件,导致疾病难以诊断和治疗。AD 的病理特征包括淀粉样斑块、神经纤维缠结和广泛的神经元丧失。β淀粉样蛋白已被广泛研究,并作为开发有效疾病修饰治疗的靶点,但在临床实践中的成功率很低。最近,神经炎症已成为 AD 进展过程中针对治疗的目标事件。包括细胞因子和趋化因子、补体系统、氧化应激和环氧化酶途径在内的各种机制途径与 AD 大脑中的神经炎症有关。包括小胶质细胞、星形胶质细胞和少突胶质细胞在内的许多细胞共同作用,以保护大脑免受损伤。本综述旨在更好地了解 AD 的炎症和免疫调节过程,以开发新型抗炎药物来减缓 AD 的进展。